Trial Profile
A Phase II study evaluating safety and efficacy of ribociclib and everolimus in patients with thyroid cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Ribociclib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 24 Jun 2017 New trial record
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology